Elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis ineligible for clinical trials: a 24-week observational study

Introduction: Seminal clinical trials with the triple combination of elexacaftor-tezacaftor-ivacaftor (ETI) demonstrated clinical efficacy in people with cystic fibrosis (pwCF) who carry at least one F508del mutation. However, due to exclusion criteria of these clinical trials, the effect of ETI was...

Descripción completa

Detalles Bibliográficos
Autores principales: Fila, Libor, Grandcourtova, Alzbeta, Bilkova, Alena, Drevinek, Pavel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275572/
https://www.ncbi.nlm.nih.gov/pubmed/37332357
http://dx.doi.org/10.3389/fphar.2023.1178009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275572/
https://www.ncbi.nlm.nih.gov/pubmed/37332357
http://dx.doi.org/10.3389/fphar.2023.1178009

Ejemplares similares